Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program

Average weight reduction in 486 patients improved from 10.5% at four months to 13.7% at one year on the Allurion Program

Separate studies with patients on GLP-1 therapy report significant weight re-gain after discontinuation of drug and lifestyle intervention program

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average weight reduction of 10.5% at four months on the Allurion Program, improving to 13.7% at one year. This data indicate that weight loss can not only be maintained by utilizing the Allurion Program, but it can also be increased by taking advantage of the Program’s ongoing virtual guidance and support.

In the study, 486 patients at a single, high-volume bariatric center were treated with the Allurion Balloon and assessed monthly with the Allurion App, Connected Scale, and Health Tracker as part of the Allurion Program. Over one year, participants were given virtual access to a team of registered dieticians. A weekly check-up was conducted for the first month, followed by biweekly check-ups for the subsequent three months, and monthly check-ups for the remaining eight months.

"This study is the largest of its kind in Southeast Asia since the Allurion Balloon was introduced in the region. Results demonstrate that the swallowable gastric balloon is an effective solution for patients seeking to lose weight and keep that weight off,” said Dr. Nik Ritza Kosai, Associate Professor and Consultant in Gastrointestinal, Obesity and Metabolic Surgery at The National University of Malaysia and lead author of the study. “Furthermore, our findings offer strong evidence that the combination of balloon intervention and one year of virtual supervision can significantly augment weight loss outcomes.”

Previous studies evaluating GLP-1 drugs indicate that after discontinuation of the drug and lifestyle intervention program, patients regained approximately two-thirds of the weight they had lost.^1-3

“While most weight loss is typically observed within the first four months on the Allurion Program while the balloon is in residence, the findings from this study demonstrate that, for these patients, the combination of the Allurion Balloon with a 12-month, structured, virtual support program significantly contributed to improved weight loss after balloon passage,” said Dr. Ram Chuttani, Chief Medical Officer of Allurion. “We believe this study validates our approach of combining the Allurion Balloon with systematic evaluation, monitoring, and guidance, offering a more effective pathway to achieving and maintaining successful weight loss outcomes.”

Sources: 1. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. 2. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. 3. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

Forward-Looking Statements

This press release may contain certain forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding the ability of the Allurion Program, which combines the Allurion Balloon with ongoing virtual guidance and support, to improve patient and clinical outcomes, including outcome improvements over time. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of Allurion to obtain and maintain regulatory approvals for and successfully commercialize the Allurion Program, including the Allurion Balloon and the VCS, (ii) the timing of, and results from, our clinical studies and trials, (iii) the evolution of the markets in which Allurion competes, (iv) the ability of Allurion to defend its intellectual property, (v) the impact of the COVID-19 pandemic, the Russia and Ukraine war, and the Israel-Hamas conflict on Allurion’s business, (vi) Allurion’s expectations regarding its market opportunities, including those for the VCS platform, and (vii) the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which Allurion operates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Allurion’s Annual Report on Form 10-K filed on March 26, 2024 (as subsequently amended) and other documents filed by Allurion from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Allurion assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Allurion does not give any assurance that it will achieve its expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240828124974/en/